Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

MHRARegulator guidanceBioequivalenceMedicinesHigh confidenceLast verified October 5, 2026

MHRA comparator product guidance

Comparator products in bioequivalence/therapeutic equivalence studies

Current edition

Last updated 20 December 2024

About this standard

Explains when a comparator product sourced outside the UK can be used in bioequivalence and therapeutic equivalence studies for abridged applications, and what bridging data are needed.

Recognition by market

Whether the market recognizes, harmonizes or adopts this standard, and which edition it accepts

No market listing is published yet.

Testing requirements that cite it

Open the market page and its pathway pages for the full requirement, protocol and report content

Related standards: JP guideline for bioequivalence studies of generic products, CPMP/EWP/QWP/1401/98 Rev 1, JP BE guideline, formulation changes (oral solid), NMPA Notice 2016 No. 61, Annex 3, FDA BE guidance for ANDAs (PK endpoints), NMPA Notice 2016 No. 61, Annex 1, HC comparative bioavailability conduct guidance, HC comparative bioavailability standards, HC foreign-sourced reference product guidance, HC proportional formulations policy, M9, M13A. See all standards.

Not legal or regulatory advice. Check the current official rules before you act. Parts of the approvals data are official open data reused under open licences. Data sources.

LinkedInLinkedInXXYouTubeYouTube